Mycosis fungoides is a disease with manifestation of the skin that has traditionally been treated with electron therapy. In this paper, we present a method of treating the entire skin with megavoltage photons using helical tomotherapy (HT), verified through a phantom study and clinical dosimetric data from our first two treated patients. A whole body phantom was fitted with a wetsuit as bolus, and scanned with computer tomography. We accounted for variations in daily setup using virtual bolus in the treatment plan optimization. Positioning robustness was tested by moving the phantom, and recalculating the dose at different positions. Patient treatments were verified with in vivo film dosimetry and dose reconstruction from daily imaging. Reconstruction of the actual delivered dose to the patients showed similar target dose as the robustness test of the phantom shifted 10 mm in all directions, indicating an appropriate approximation of the anticipated setup variation. In vivo film measurements agreed well with the calculated dose confirming the choice of both virtual and physical bolus parameters. Despite the complexity of the treatment, HT was shown to be a robust and feasible technique for total skin irradiation. We believe that this technique can provide a viable option for Tomotherapy centers without electron beam capability. 
lower, which allows re-irradiation. To cover as large an area of the skin as possible, TSEBT is administered with the patient standing on a rotating platform or at several fixed positions at an extended source to skin distance (SSD) of 3-8 m using a beam degrader.
TSEBT offers good short-term remission and few reported cases of severe toxicity. 4 However, it is not possible to irradiate all the cutaneous tissue with this technique, and several patch fields are needed, raising questions regarding over-and underdosage at the field junctions. In addition, lead shielding of genitals, eyes and lips is necessary, making the technique cumbersome.
An alternative mode of treatment is total skin irradiation (TSI) with helical tomotherapy (HT), 6 a technique combining couch translation and continuous gantry rotation. With this technique, 7, 8 targets as long as 135 cm can be irradiated in one field. 9 Treatment of longer targets requires the field to be split but still allowing the whole skin to be treated on one occasion. Furthermore, skin folds can be covered by defining them as target in the optimization, and organs such as the eyes, genitals and lips can be avoided. For TSI with HT, the patient can lie down in supine position during the entire treatment as opposed to standing. This technique can be of value for centers without capability of electron treatment of the entire skin, but also for partial irradiation of the skin. A few studies have previously reported on TSI with HT, 7, 10, 11 In this work, we evaluate the robustness of TSI with HT and implementation of virtual and physical bolus in the form of a wet suit and verify phantom data with clinical data.
The feasibility, deliverability, and assessment of robustness for the first two patients treated at our clinic is described.
| MATERIALS AND METHODS

2.A | Overview
Several issues regarding patient positioning, treatment planning, and delivery needed to be addressed before commencing clinical TSI.
In order to achieve a geometrically robust treatment plan, a virtual bolus was designed and applied in the optimization. To test the robustness of the treatment plan, a whole body phantom was shifted and recalculated in the planning system for several positions and verified with dose measurements. Since the dose delivery of TSI is extremely complex, given that only tangential beams are used, the dose calculation accuracy of the treatment planning system (TPS) was verified for both surface dose and scattered central dose. During treatment, the patients were fitted with a wet suit of Neoprene, which is a non-tissue equivalent material of unknown electron density and hence the bolus effect of Neoprene needed to be carefully evaluated. In vivo measurements were performed to verify the dose to the skin, on both patients and phantom.
2.B | Patient characteristics
The first patient was a 72-yr-old male diagnosed with MF 2003. He had previously received radiotherapy with kilovoltage x-ray on several occasions and had also been treated with PUVA + Methotrexate, Neotigason, and Targretin. At the time of TSI he had patches and plaques covering more than 10% of the body surface. she had patches and plaques covering more than 10% of the body surface. The TSI treatment was followed by a haploidentical allogenic bone marrow transplant with her 18-yr-old daughter as donor 3 weeks after the last fraction.
2.C | Phantoms and detectors
A number of phantoms and detectors were used in this study.
• An anthropomorphic whole body phantom, PH-2B CT (PBU-60) (Kyoto Kagaku, Kyoto, Japan), with and without a neoprene suit.
The density of simulated soft tissue of the phantom is 1.061 g/cm 3 , with a relative electron density of 0.975. The weight is 50 kg and the length 165 cm. The phantom includes relevant organs such as a lung cavity and a synthetic skeleton.
• A TomoTherapy phantom (Accuray Inc., Madison, WI, USA), which is a cylindrical Solid Water (RMI Gammex) phantom with varying density plugs, inserts for an A1SL ion chamber, and a removable midsection for film dosimetry.
• Solid Water slabs, size of 550 × 150 mm with thicknesses of 5-50 mm.
• A Delta4 1042 cross-plane PMMA diode array detector with a density of 1.19 g/cm 3 and relative electron density of 1.16 (Scandidos, Uppsala, Sweden).
• Two separate Exradin A1SL ion chamber (Standard Imaging Inc., Middleton, WI, USA).
• Gafchromic EBT3 film (ISP, Wayne, NJ, USA) together with evaluation software FilmQA Pro (Ashland, Bridgewater, NJ, USA) and an
Epson 4990 flatbed scanner (Seiko Epson Corporation, Nagano, Japan). These structures were cropped from the PTV inwards by 5, 15, and 30 mm, where the 30-mm structure were set to completely block the fluence. This procedure prevented all except tangential beams from entering the patient/phantom, thus reducing the dose to deep-lying organs. The aim of planning optimization was to achieve the prescribed dose to cover 60% of the PTV, and a minimum of 95% of the prescribed dose would cover 95% of the PTV.
2.D |
The shape of the blocking structures was modified until target coverage was deemed acceptable.
The field junction was designed to be robust for uncertainties in patient positioning. A dose gradient was achieved on both CT sets by contouring a junction structure centered at the junction markers in the longitudinal direction. We started with a 4 cm long junction structure and then adjusted the length until coverage was acceptable. The junction structure was set as a target structure, without setting the structure in use and with an overlap priority higher than 
2.E.2 | Patient
The prescribed dose was defined as 12 Gy in six fractions for the first patient whereas the second patient was prescribed 20 Gy in ten fractions. Planning and optimization were performed using similar planning parameters as in the phantom study, with several internal
The anthropomorphic whole body PBU-60 phantom, immobilized by a large vacuum cushion, with and without the wetsuit, showing the thermoplastic mask and support under the knees. Red circles mark the position of the internal reference points for the two plans and the blue line marks the position of the field junction.
blocking structures to prevent dose to internal organs such as bone marrow.
2.F | Virtual bolus
A virtual bolus was used to prevent over-optimization of the fluence in air, due to expansion of the PTV outside the body. The wet suit was replaced by virtual bolus in the optimization since the fit of the suit varied from day to day. Targets very close to the tissue-air border causes the TPS to compensate the fluence to achieve full dose in the build-up region and in the air surrounding the body. If the patient is not perfectly aligned during treatment, the patient may receive a dose well above that prescribed during treatment (Fig. 2 ).
This can be managed by using a virtual bolus.
2.F.1 | Phantom
With the whole body phantom, optimization tests were performed in the TPS using a varying bolus density of 0, 0.4, and 1.0 g/cm 3 .
The thickness of the virtual bolus was 8 mm, that is, the PTV with an additional 3 mm margin, as suggested by Moliner. 
2.F.2 | Patients
Although the patients were CT-scanned wearing the full wet suit, a virtual bolus of water of specified density was still added in the TPS for two reasons; to account for daily variations caused by the fit of the wet suit and secondly, to replace the unconventional bolus material of neoprene with a material of well-known dosimetric properties. The bolus was applied uniformly over the entire skin.
2.G | Physical bolus
2.G.1 | Phantom
A 7 mm thick foamed neoprene (polychloroprene), wetsuit (AquaLung Dive, US) was used as a physical bolus for the PBU-60 phantom. A wetsuit was chosen as bolus since it can be made to cover almost the entire body, has a uniform thickness and no metal components. The wetsuit covered the entire phantom except hands, feet and head.
2.G.2 | Patients
For the patients, a hood, gloves, and socks of neoprene were also added. In addition, patient #2 had a 5 mm water equivalent bolus (Superflab bolus, Radiation Products Design Inc., Albertville, MN, USA) covering eye lids and forehead, due to lesions in the face. The hood was open in the face but covering chin, ears, and above hair line.
2.H | Robustness tests 2.H.1 | Phantom
To verify the geometric robustness of the technique using a virtual bolus of 0.4 g/cm 3 of 8 mm thickness together with a 7 mm neoprene bolus, the final treatment plans were exported to the built-in module for DQA. This module can be used to recalculate treatment plans for different geometries and phantoms. In this study, the treatment plan was recalculated for the upper body omitting the virtual bolus. The PBU-60 phantom was then repositioned by ±10 mm in the longitudinal, vertical, and lateral directions. The resulting dose matrices were exported to the Eclipse TPS for summation and comparison. One strip from each sheet was irradiated with 2 Gy at a depth of 1.5 cm in Solid Water and used as a dose reference.
Patients
To assess the patient dose to the skin at treatment, we performed in vivo dosimetry with EBT3 film at the first fraction. At least 20 film strips of 1 × 1.5 cm 2 were taped on several positions on the patients' skin. A reference irradiation was performed at 2 Gy in solid water at 1.5 cm depth with a minimum of 20 cm backscatter.
2.I.2 | Bolus measurement
The bolus effect of the neoprene wet suit fitted on the PBU phantom was quantified by paired film measurements, where film where placed beneath the wetsuit for the first measurements and replaced for the second measurement without wetsuit. In addition, a strip of film was placed on a 20 cm thick Solid Water slab and irradiated with and without a 200 × 200 × 7 mm 3 square of neoprene to measure the buildup effect of neoprene. We compared the two measured groups using Wilcoxon signed-rank test.
2.I.3 | Film evaluation
Prior to each film measurement, a strip of film from the same sheet as that used for measuring was irradiated with 2 Gy at depth of 1.5 cm in
Solid Surface dose measurement were compared to the calculated dose in the TPS, obtained with the plan recalculated without the virtual bolus.
2.J | Ion chamber measurements
The optimized plan, restricted to only tangential irradiation was delivered to the cylindrical Tomotherapy phantom, to verify the accuracy of the dose calculation algorithm of the TomoTherapy TPS, at depths far from the main interaction sites. The plan was optimized with the phantom surface as target, to 4 Gy per fraction, and with margins and a virtual bolus specification identical to those used for the whole body phantom. The depth dose was measured using two A1SL ion chambers at several positions in the phantom and compared to the dose calculated by the TPS.
2.K | Diode array measurements
Dose verification was also performed using the Delta4 diode array detector placed at several locations to cover the entire irradiation volume of the treatment plan. The measured dose was compared to the planned dose using gamma evaluation. 14 Quality control (QC) acceptance criterion was set to 90% pass rate using 2 mm distance to agreement, 3% dose difference, and global dose normalization.
The dose delivery across the junction was verified by irradiating both plans using the Delta4 detector in the same measurement session. For both plans, we positioned the Delta4 at the lateral and sagittal green laser position and longitudinally in the plan junction markers, due to the red to green laser separation limit of 15 cm for.
The distance from the longitudinal green laser position to the Delta4 was measured in the DQA module and applied at setup. After irradiation of the upper plan, the detector was rotated and aligned to the lasers for the lower plan and subsequently irradiated in the same measurement session. The planned dose for the upper and lower body was manually summed using Python.
| RESULTS
3.A | Phantom
Doses to OARs are presented in Table 1 . The optimization time for 500 iterations ranged between 4 and 6 h with a GPU-assisted dose calculation engine. The beam on-times for the final plan were 31 and tion, some adjustment of the blocking structure was required to compensate for the flat back of the phantom (see Fig. 3 ). This adjustment resulted in higher dose to the lungs of the phantom, due to the thin thorax wall of the PBU-60 phantom (6 mm). For the patients, this was corrected for by immobilizing the back in a rounded position.
Verification of the dose to the surface of the whole body phantom using EBT3 film agreed well with the dose to the PBU-60 phantom calculated without the virtual bolus. The results indicate that the dose calculated in the TPS provides a good approximation of the delivered skin dose. When using the virtual bolus and neoprene for build-up, the average dose difference between TPS and film measurements was −0.6% (SD = 3%; Fig. 4) . The paired measurements, with and without wet suit, on the PBU-60 phantom showed a significantly higher surface dose with the 7 mm neoprene bolus than irradiation without bolus (Wilcoxon signed-rank test, P < 0.05; , and 1 g/cm 3 , respectively, justifying the use of a virtual bolus with a density lower than that of water as proposed by
Moliner et al. 13 The extension of the junction structure between the lower and upper body of the PBU-60 was adjusted until an acceptable dose distribution was achieved, which was 4. Delta4 as compared to planned dose recalculated on the Delta4 and summed over the junction region are reported in Fig. 6 , and line profiles of the junction for different total length of the junction structure in Fig. 7 .
3.B | Patient
Based on the experience from the immobilization of the PBU-60 phantom, the patients were immobilized with the back in a laterally curved position to better facilitate tangential irradiation in the optimization.
For both patients, the six-first fractions were recalculated based on daily MVCT images and compared to the robustness calculations performed with the PBU-60 phantom (Fig. 8) . In addition, in vivo film dosimetry corresponded well with dose calculated in TPS, with a mean difference from TPS of 5.3% (SD = 11.9%) and 1.5% (SD = 9.0%) for patient 1 and 2 respectively (Fig. 9) . Robustness test of the junction dose performed on the first patient yielded an average D 98% of 10.8 Gy (SD = 0.2 Gy) and D 2% of 13.4 Gy (SD = 0.2 Gy) for 5 mm translations.
Both patients could put the wetsuit on within a few minutes, with no notable effort. The fit for patient 2 was not optimal which was compensated for by taping air gaps to achieve a snug fit. Figure 10 shows F I G . 5. Measurements with and without wet suit using electron beam therapy 3 film on the PBU-60 phantom presented as a boxand-whisker plot. The median (red line), as well as first and third quartile (box) and 1.5 times past the interquartile range (outer line) is plotted with outliers (black points). Dose is presented as percentage of prescribed dose.
skin delivery, despite the fact that neoprene is not a standard material, and the lack of water equivalence in the material. The results quantify the difference with using neoprene as bolus and stands in contrast to other studies that did not find it necessary to use bolus for skin irradiation. 8, 16 The dosimetric advantage to a non-bolus treatment is clear, any attempt at optimizing or deliver photons to the skin performs better with bolus added.
4.B | Robustness
The robustness test showed that calculated and delivered dose corresponded well for displacements up to 10 mm, despite a CTV-to-PTV margin of only 5 mm. Underdosage to the skin of up to 20%, and an increase in average dose to the target, have been reported previously, 8 depending on the parameters of the virtual bolus. When a thick high-density virtual bolus is used, the lack of corresponding physical bolus at treatment delivery causes overdosage to the skin and to a depth up to a few centimeters. When no bolus is used, physical or virtual, underdosage of the skin is likely due to build-up, and large dose deviations can be expected with normal patient dis- OARs in this study are similar to, or slightly higher than, those reported previously. 7, 8 These differences can be attributed to differences in CTV-to-PTV margins or differences in phantom anatomy.
The methodology for matching the junction dose of the treatment plans worked well for the treated patients and the phantom, but the dose distribution was more heterogeneous than in other parts of the target. The effect of using an overlapping structure works similar to cropping the PTV, but the benefit of a junction structure was the ability of adjusting the overlap region and still get the dose coverage correct in the PTV used for optimization. The upper and lower body plan was summed in Eclipse and the line profile was acquired at 3 mm depth centered lateral over the junction marker.
day. However, no repositioning was needed, indicating that the skin folds was considered within tolerance. These issues affected the delivered dose as seen by the daily fraction calculations in and should be addressed by focusing on proper fitting of the wet suit.
Another learning experience was to keep the arms close to the body.
Although arms positioned farther from the thorax facilitate optimization of the arm circumference, it counteracts the optimization of dose homogeneity to the arms. As shown by in vivo film measurements, the measured dose to the skin was closer to the predicted (1.5%-5.3%) than reported in other studies with different physical and virtual bolus. 7, 8 Previous studies on skin doses in the tomotherapy TPS has shown an overestimation of the calculated dose by approximately 9%. 17, 18 The number of patients in the study makes this a first experience, and more patients need to be added to draw any general conclusions. A clinical study is in the planning phase.
4.C | Comparison to standard treatment
TSEBT is today regarded as the standard treatment of mucosis fungoides and in comparison, TSI using HT is a lengthy and complex Similar to results reported by Buglione et al. 16 we believe TSI with TT to be a complement to electron treatment and in certain cases where treatment with Tomotherapy could be beneficial. In addition, since TSI with HT is an image guided technique, problems that may arise during treatment can be evaluated by dose recalculation or re-optimization of the treatment plan. Previously treated areas and organs at risks can be avoided, and simultaneous integrated boost to for example, plaque areas can be implemented.
The results from this study can be of use when treating patients with partial irradiation of large areas, especially of convex shape such as the scalp 20 or melanoma. 21 Furthermore, this technique may be an alternative to centers where electron therapy is not available.
4.D | Film dosimetry
The EBT3 film is an established and appropriate dosimetry system for surface dose measurement. [22] [23] [24] It has a low angle dependence and stable response over a wide dose and energy range, especially when used with the FilmQApro scanning system, where all color channels can be evaluated. The largest uncertainty stems from positioning accuracy, that is, the problem to correctly assess the points of measurement of the films in the TPS for correct dose comparison. 
